secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001437749-26-011597
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed presents neflamapimod Phase 3 design and MRI data at LBD Annual Meeting
--------------------------------------------------------------------------------

- New MRI analyses from Phase 2b RewinD-LB trial show neflamapimod may reduce basal forebrain atrophy in DLB.
- Global regulatory alignment achieved; Phase 3 trial design finalized.
- Plasma GFAP biomarker correlates with cognitive decline and is responsive to neflamapimod treatment.
- Additional MRI data to be presented at AAN Annual Meeting on April 22, 2026.
- No approved treatments for DLB in US or EU; neflamapimod aims to be first.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926011597/0001437749-26-011597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926011597/crvo20260407_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-011597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer